Inactive Instrument

Analyst Reco. Bausch Health Companies Inc Toronto S.E.

Equities

CA91911K1021

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating	04-23	MT
Trump eyes $43 million haul from biggest fundraiser yet	04-06	RE
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	04-05	MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating	02-23	MT
RBC Cuts Price Target on Bausch Health to $8 From $9 Ahead of Q3 Report, Keeps Sector Perform Rating	23-10-23	MT
Jefferies Upgrades Bausch Health to Buy From Hold, Adjusts Price Target to $16 From $9	23-09-20	MT
RBC Boosts Price Target on Bausch Health to $9 From $8 Ahead of Q2 Report, Maintains Sector Perform Rating	23-07-24	MT
TD Cowen Downgrades Bausch Health to Market Perform From Outperform, Adjusts Price Target to $12 From $35	23-06-16	MT
Jefferies Adjusts Price Target on Bausch Health to $9.50 From $7, Maintains Hold Rating	23-05-22	MT
RBC Cuts Price Target on Bausch Health to $8 From $9, Notes Concerns for Ability to Distribute Bausch + Lomb Shares, Keeps Sector Perform Rating	23-05-05	MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Maintains Sector Perform Rating	23-02-24	MT
Piper Sandler Adjusts Bausch Health Cos.' Price Target to $6 from $7, Reiterates Neutral Rating	22-09-09	MT
RBC Capital Adjusts Bausch Health Price Target to $8 From $4.50, Maintains Sector Perform Rating	22-09-01	MT
Stifel Nicolaus Adjusts Price Target for Bausch Health Companies to $15 From $40, Maintains Buy Rating	22-08-10	MT
BMO Capital Reviews Bausch Health's Q2	22-08-10	MT
RBC Capital Reviews Bausch Health's Q2, Trims Target to US$4.50	22-08-10	MT
BMO Capital Lowers Bausch Health Companies' Price Target to $8 From $15, Maintains Market Perform Rating	22-08-10	MT
Fitch Cuts Bausch Health's Issuer Default Rating; Placed on Rating Watch Negative	22-08-04	MT
Fitch Downgrades Bausch + Lomb Corporation's IDR to 'B+'; Revised Rating Watch to Evolving	22-08-04	AQ
RBC Downgrades Bausch Health to Sector Perform From Outperform, Cuts Price Target to $5 From $12 on Expected Early Xifaxan Patent Loss	22-07-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bausch Health Companies Inc Toronto S.E.

Equities

CA91911K1021

Analyst Reco.

Filters